Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.

Experimental hematology - 1 Jul 2020

Yan Bowen, Claxton David, Huang Suming, Qiu Yi

Abstract excerpt

Acute myeloid leukemia (AML) is a heterogeneous clonal disease characterized by the proliferation and accumulation of myeloid blast cells in the bone marrow, which eventually lead to hematopoietic failure. Chemoresistance presents as a major burden for therapy of AML patients. p53 is the most important tumor suppressor protein that regulates cellular response to various stress. It is also important for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Hematopoiesis
Share to Hematopoietic Stem Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Neoplastic Stem Cells

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 32569759
DOI: 10.1016/j.exphem.2020.06.003
PMCID: PMC7416446

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.PMID 32569759Read ↗

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?Semantic proximity Read ↗

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation.Semantic proximity Read ↗

TP53 Mutation in Acute Myeloid Leukemia: An Old Foe RevisitedSemantic proximity Read ↗

[Advances in the Treatment of Acute Myeloid Leukemia with TP53 Mutations-Review].Semantic proximity Read ↗

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read ↗

Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia.Semantic proximity Read ↗

The role of TP53 in acute myeloid leukemia: Challenges and opportunitiesSemantic proximity Read ↗

Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.Semantic proximity Read ↗

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.Semantic proximity Read ↗

The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AMLSemantic proximity Read ↗

TP53 signal pathway confers potential therapy target in acute myeloid leukemia.Semantic proximity Read ↗

Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.